Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696123 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TSHRHTTATMNPSR1 | |
| SCHEMBL4311915 | 0.93 | SLC29A1 (0.33) | ALDH1A1TSHRHTTATMNPSR1 | |
| SCHEMBL10703373 | 0.88 | LMNA (0.39) | ALDH1A1TSHRHTTATMNPSR1 | |
| SCHEMBL14829804 | 0.85 | TSHR (0.43) | ALDH1A1TSHRCYP2C19CYP1A2LMNA | |
| SCHEMBL10045158 | 0.85 | CYP2C19 (0.48) | ALDH1A1TSHRCYP2C19CYP1A2LMNA | |
| SCHEMBL10045163 | 0.85 | CYP2C19 (0.48) | ALDH1A1TSHRCYP2C19CYP1A2LMNA | |
| SCHEMBL13740992 | 0.84 | ALDH1A1 (0.35) | ALDH1A1TSHRCYP2C19CYP1A2LMNA | |
| SCHEMBL438190 | 0.82 | — | — | |
| SCHEMBL10045165 | 0.82 | CYP2C19 (0.46) | ALDH1A1TSHRCYP2C19CYP1A2LMNA | |
| Hydrochloric Acid SCHEMBL602920 | 0.82 | LMNA (0.37) | ALDH1A1TSHRHTTATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004533516-A | — | — | 2004-11-04 | — | — | JP | claimed |
| US-20040134838-A1 | Method of refining crude oils having organic acidity | TOTAL FRANCE (FR) | 2004-07-15 | — | — | US | claimed |
| EP-1397468-A1 | METHOD OF REFINING CRUDE OILS HAVING HIGH ORGANIC ACIDITY | Total France (FR) | 2004-03-17 | — | — | EP | claimed |
| WO-2002097014-A1 | METHOD OF REFINING CRUDE OILS HAVING HIGH ORGANIC ACIDITY | TOTAL FRANCE (FR) | 2002-12-05 | — | — | WO | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20040134838-A1 | Method of refining crude oils having organic acidity | TOTAL FRANCE (FR) | 2004-07-15 | — | — | US | disclosed |
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| EP-1397468-A1 | METHOD OF REFINING CRUDE OILS HAVING HIGH ORGANIC ACIDITY | Total France (FR) | 2004-03-17 | — | — | EP | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| WO-2002097014-A1 | METHOD OF REFINING CRUDE OILS HAVING HIGH ORGANIC ACIDITY | TOTAL FRANCE (FR) | 2002-12-05 | — | — | WO | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | ALDH1A1 1309/4885TSHR 580/4885HTT 2515/4885 |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | ALDH1A1 1707/4885TSHR 3563/4885HTT 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.